Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16–12)

• Published in: Breast (Edinburgh) 2020-02, Vol.49, p.41-47
• Main Authors: Kim, Jae Sik, Kim, Kyubo, Jung, Wonguen, Shin, Kyung Hwan, Im, Seock-Ah, Kim, Hee-Jun, Kim, Yong Bae, Chang, Jee Suk, Choi, Doo Ho, Park, Yeon Hee, Kim, Dae Yong, Kim, Tae Hyun, Choi, Byung Ock, Lee, Sea-Won, Kim, Suzy, Kwon, Jeanny, Kang, Ki Mun, Chung, Woong-Ki, Kim, Kyung Su, Nam, Ji Ho, Yoon, Won Sup, Kim, Jin Hee, Cha, Jihye, Oh, Yoon Kyeong, Kim, In Ah
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Brain metastasis; Brain Neoplasms - mortality; Brain Neoplasms - radiotherapy; Brain Neoplasms - secondary; Breast cancer; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Carcinoma, Ductal, Breast - mortality; Carcinoma, Ductal, Breast - radiotherapy; Carcinoma, Ductal, Breast - secondary; Carcinoma, Lobular - mortality; Carcinoma, Lobular - radiotherapy; Carcinoma, Lobular - secondary; Female; Follow-Up Studies; Humans; Middle Aged; Original; Overall survival; Prognosis; Prognostic model; Republic of Korea - epidemiology; Retrospective Studies; Survival Analysis; Whole brain radiotherapy
• ISSN: 0960-9776; 1532-3080
• DOI: 10.1016/j.breast.2019.10.007

This study evaluated the influence of prognostic factors and whole brain radiotherapy (WBRT) on overall survival (OS) of breast cancer (BC) patients with brain metastases (BM). Medical records of 730 BC patients diagnosed with BM from 2000 to 2014 at 17 institutions were retrospectively reviewed. OS was calculated from BM diagnosis. Median follow-up duration was 11.9 months (range, 0.1–126.2). Median OS was 15.0 months (95% CI: 14.0–16.9). Patients with different BC-specific graded prognostic assessment (GPA) scores showed significant differences (p